These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38913220)

  • 21. Nonvitamin K Antagonist Oral Anticoagulants Use in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves/Prior Surgical Valve Repair: A Multicenter Clinical Practice Experience.
    Russo V; Attena E; Mazzone C; Esposito F; Parisi V; Bancone C; Rago A; Nigro G; Sangiuolo R; D' Onofrio A
    Semin Thromb Hemost; 2018 Jun; 44(4):364-369. PubMed ID: 29304513
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR.
    Van Mieghem NM; Unverdorben M; Hengstenberg C; Möllmann H; Mehran R; López-Otero D; Nombela-Franco L; Moreno R; Nordbeck P; Thiele H; Lang I; Zamorano JL; Shawl F; Yamamoto M; Watanabe Y; Hayashida K; Hambrecht R; Meincke F; Vranckx P; Jin J; Boersma E; Rodés-Cabau J; Ohlmann P; Capranzano P; Kim HS; Pilgrim T; Anderson R; Baber U; Duggal A; Laeis P; Lanz H; Chen C; Valgimigli M; Veltkamp R; Saito S; Dangas GD;
    N Engl J Med; 2021 Dec; 385(23):2150-2160. PubMed ID: 34449183
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Edoxaban for the management of elderly Japanese patients with atrial fibrillation ineligible for standard oral anticoagulant therapies: Rationale and design of the ELDERCARE-AF study.
    Okumura K; Lip GYH; Akao M; Tanizawa K; Fukuzawa M; Abe K; Akishita M; Yamashita T
    Am Heart J; 2017 Dec; 194():99-106. PubMed ID: 29223441
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Edoxaban Versus Dual Antiplatelet Therapy for Leaflet Thrombosis and Cerebral Thromboembolism After TAVR: The ADAPT-TAVR Randomized Clinical Trial.
    Park DW; Ahn JM; Kang DY; Kim KW; Koo HJ; Yang DH; Jung SC; Kim B; Wong YTA; Lam CCS; Yin WH; Wei J; Lee YT; Kao HL; Lin MS; Ko TY; Kim WJ; Kang SH; Yun SC; Lee SA; Ko E; Park H; Kim DH; Kang JW; Lee JH; Park SJ;
    Circulation; 2022 Aug; 146(6):466-479. PubMed ID: 35373583
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Edoxaban Versus Warfarin in Patients With Atrial Fibrillation and History of Liver Disease.
    Qamar A; Antman EM; Ruff CT; Nordio F; Murphy SA; Grip LT; Greenberger NJ; Yin OQP; Choi Y; Lanz HJ; Mercuri MF; Braunwald E; Giugliano RP
    J Am Coll Cardiol; 2019 Jul; 74(2):179-189. PubMed ID: 31296289
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and Safety of Renal Function on Edoxaban Versus Warfarin for Atrial Fibrillation: A Systematic Review and Meta-Analysis.
    Wang Y; Li L; Wei Z; Lu S; Liu W; Zhang J; Feng J; Wang D
    Medicines (Basel); 2023 Jan; 10(1):. PubMed ID: 36662497
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Non-vitamin K versus vitamin K antagonist oral anticoagulants in surgical mitral valve repair or bioprosthetic valve replacement in the first three months after surgery.
    Costa H; Custódio P; Baptista Gonçalves R; Lamares Magro P; Sousa Uva M
    Rev Port Cardiol; 2024 Sep; 43(9):501-509. PubMed ID: 38945474
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Edoxaban versus warfarin in vitamin K antagonist experienced and naïve patients from the edoxaban versus warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomised trial.
    Kozieł M; Al-Saady N; Hjortshøj SP; Goudev A; Huber K; Cohen A; Jin J; Melino M; Winters SM; Goette A; Lip GYH
    Clin Res Cardiol; 2020 Aug; 109(8):1018-1024. PubMed ID: 31915996
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment Satisfaction and Convenience for Patients With Atrial Fibrillation on Edoxaban or Vitamin K Antagonists After Transcatheter Aortic Valve Replacement: A Post Hoc Analysis from the ENVISAGE-TAVI AF Trial.
    Hengstenberg C; Van Mieghem NM; Wang R; Ye X; Shi L; Guo S; Chen C; Jin J; Ye X; Dangas G; Unverdorben M
    Am J Cardiol; 2023 Dec; 209():212-219. PubMed ID: 37848174
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Edoxaban Versus standard of care and their effects on clinical outcomes in patients having undergone Transcatheter Aortic Valve Implantation in Atrial Fibrillation-Rationale and design of the ENVISAGE-TAVI AF trial.
    Van Mieghem NM; Unverdorben M; Valgimigli M; Mehran R; Boersma E; Baber U; Hengstenberg C; Shi M; Chen C; Saito S; Veltkamp R; Vranckx P; Dangas GD
    Am Heart J; 2018 Nov; 205():63-69. PubMed ID: 30172099
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of mitral versus aortic bioprosthetic valve position on thromboembolism and bleeding risk in patients with atrial fibrillation.
    Obayashi Y; Miyake M; Amano M; Kitai T; Takegami M; Nishimura K; Tamura T; Furukawa Y; Izumi C
    J Cardiol; 2022 Feb; 79(2):226-232. PubMed ID: 34716054
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
    Ruff CT; Giugliano RP; Braunwald E; Morrow DA; Murphy SA; Kuder JF; Deenadayalu N; Jarolim P; Betcher J; Shi M; Brown K; Patel I; Mercuri M; Antman EM
    Lancet; 2015 Jun; 385(9984):2288-95. PubMed ID: 25769361
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease.
    Kimachi M; Furukawa TA; Kimachi K; Goto Y; Fukuma S; Fukuhara S
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD011373. PubMed ID: 29105079
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rationale and design of PROACT Xa: A randomized, multicenter, open-label, clinical trial to evaluate the efficacy and safety of apixaban versus warfarin in patients with a mechanical On-X Aortic Heart Valve.
    Jawitz OK; Wang TY; Lopes RD; Chavez A; Boyer B; Kim H; Anstrom KJ; Becker RC; Blackstone E; Ruel M; Thourani VH; Puskas JD; Gerdisch MW; Johnston D; Capps S; Alexander JH; Svensson LG
    Am Heart J; 2020 Sep; 227():91-99. PubMed ID: 32693197
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Phase III Atrial Fibrillation Trials.
    Renda G; di Nicola M; De Caterina R
    Am J Med; 2015 Sep; 128(9):1007-14.e2. PubMed ID: 25910790
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low-intensity oral anticoagulant plus low-dose aspirin during the first six months versus standard-intensity oral anticoagulant therapy after mechanical heart valve replacement: a pilot study of low-intensity warfarin and aspirin in cardiac prostheses (LIWACAP).
    Pengo V; Palareti G; Cucchini U; Molinatti M; Del Bono R; Baudo F; Ghirarduzzi A; Pegoraro C; Iliceto S;
    Clin Appl Thromb Hemost; 2007 Jul; 13(3):241-8. PubMed ID: 17636186
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of warfarin therapy duration after bioprosthetic aortic valve replacement with risk of mortality, thromboembolic complications, and bleeding.
    Mérie C; Køber L; Skov Olsen P; Andersson C; Gislason G; Skov Jensen J; Torp-Pedersen C
    JAMA; 2012 Nov; 308(20):2118-25. PubMed ID: 23188028
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and Safety of Nonvitamin K Oral Anticoagulants following Cardiac Valve Replacement.
    Stuart MK; Blackwell SB; Holder HB; Wood EL; Starr JA
    South Med J; 2021 Jan; 114(1):46-50. PubMed ID: 33398361
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antithrombotic Therapy for Patients With Atrial Fibrillation and Bioprosthetic Valves　- Real-World Data From the Multicenter, Prospective, Observational BPV-AF Registry.
    Izumi C; Miyake M; Fujita T; Koyama T; Tanaka H; Ando K; Komiya T; Izumo M; Kawai H; Eishi K; Yoshida K; Kimura T; Nawada R; Sakamoto T; Shibata Y; Fukui T; Minatoya K; Tsujita K; Sakata Y; Takegami M; Kimura T; Sugio K; Takita A; Nishimura K; Furukawa Y;
    Circ J; 2022 Feb; 86(3):440-448. PubMed ID: 34719560
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of warfarin on cardiac and cerebrovascular events following bioprosthetic aortic valve replacement: A nationwide cohort study.
    Chang WT; Ho CH; Chang CL; Cheng BC; Wu NC; Chen ZC
    J Thorac Cardiovasc Surg; 2020 May; 159(5):1730-1739.e1. PubMed ID: 31208804
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.